Skip to main content
Equibles
VOR logo

VOR · Vor Biopharma Inc.

Track VOR — free

Use VOR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about VOR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$23.07 -0.51 (-2.16%)
Market Cap
$1.36B
Shares
59.16M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$23.58 Open$24.05 Day$23.56–24.54 Since split$6.86–48.72 Avg vol 30d918K Short int7.3M · 12.3% float · 8.3d Short vol69% DataSep 2025–Aug 2026 Filing10-Q · Aug 11

Raw chart and full-history price indicators begin at the captured split on Sep 19, 2025; bars on opposite sides are not compared.

The closing range begins at the captured split on Sep 19, 2025.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +55%
above
Price vs 50-day avg +24%
above
RSI (14) 65
neutral
MACD trend Negative
52-week position 40%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +21%
trailing
6-month return +48%
trailing
YTD return +80%
this year
Relative strength +37%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow Accumulating
+26% holders QoQ · +38 funds added
Insider flow Distributing
Net -$4.2K over 90 days · 100% sells
Short interest Falling
12.26% of float · ▼ -0.5% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
101 holders — near 3-yr high, broad support
Squeeze score 85
high risk · 0–100
Fundamentals
Weak
EPS growth −107%
Y/Y
Free cash flow $-143.7M
Balance sheet $396.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 116%
annualized · 1-yr
Max drawdown −86%
past year
ATR 5.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+55% Bullish
Price vs 50-day avg
+24% Bullish
RSI (14)
65 Neutral
MACD trend
Negative Bearish
52-week position
40% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow Accumulating
+26% holders QoQ · +38 funds added
Insider flow Distributing
Net -$4.2K over 90 days · 100% sells
Short interest Falling
12.26% of float · ▼ -0.5% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
101 holders — near 3-yr high, broad support
Price context
position in its range since split · 2025-09-19
Range low $7 Now $24 · 40% Range high $49
vs 200-day avg +55% vs 50-day avg +24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and short-term investments $450M fiscal year ended December 31, 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VOR
Vor Biopharma Inc.
this stock
$1.36B +80.3% — — 12.3%
ONC
BeOne Medicines Ltd.
 $557.05B +24.0% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +21.8% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +8.9% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +491.3% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
101
% held
82.1%
Net QoQ
+7.9M sh
Top holder
TCG Crossover Management,…
Held Float
View
Held by Funds
Fund positions
46
View
Short & Settlement
Short Interest Falling
Shares short
7.3M
Days to cover
8.3d
Change
-37.4K sh
View
Short Volume
Short vol %
69%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
419
Value
$8.2K
As of
Jul 23, 2026
View
Off-Exchange
Off-exchange %
40.0%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$4.2K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-696.0M
EPS diluted
$-70.50
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 11, 2026
This year
11
View
Proposed Sales
Value
$2.3M
Shares
76.9K
Filed
Oct 20, 2025
View
Exempt Offerings
Offering
$110.1M
Filed
Jul 10, 2020
View
Earnings & Events
Earnings Calls
Last call
Jun 3, 2026
View

Performance

Raw-price comparisons begin at the captured split on Sep 19, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
VOR +5.6% +20.9% +48.3% +11.5% +80.3%
SPY -0.4% +2.9% +11.6% +3.0% +12.8%
vs SPY +6.0% +18.0% +36.7% +8.5% +67.5%
Key facts CIK 1817229 CUSIP 929033207 13F (30d) 107 filings 103 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)